Alembic Pharmaceuticals is currently trading at Rs. 616.05, up by 7.95 points or 1.31% from its previous closing of Rs. 608.10 on the BSE.
The scrip opened at Rs. 619.35 and has touched a high and low of Rs. 621.00 and Rs. 614.00 respectively. So far 992 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 2 has touched a 52 week high of Rs. 664.00 on 27-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.
Last one week high and low of the scrip stood at Rs. 621.00 and Rs. 576.00 respectively. The current market cap of the company is Rs. 11613.52 crore.
The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 14.88% and 12.16% respectively.
Alembic Pharmaceuticals and Orbicular Pharmaceutical Technologies’ Joint Venture (JV) Company — Aleor Dermaceuticals has successfully cleared its first United States Food and Drugs Administration (USFDA) inspection of its new formulation manufacturing facility located at Karakhadi in the state of Gujarat; without any observations. The scheduled inspection was carried out between October 15, 2018 and October 19, 2018.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.